Table 3.
Mortality and duration of major therapeutic interventions used, and length of stay in ICU and hospital for patients treated with or without IVIgG
| Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| IVIgG(+) (n = 960) |
IVIgG(–) (n = 2158) |
p value | IVIgG(+) (n = 653) |
IVIgG(–) (n = 653) |
p value | |
| Mortality | ||||||
| ICU mortality (%) | 219 (22.8) | 376 (17.4) | <0.001 | 137 (21.0) | 118 (18.1) | 0.185 |
| In-hospital mortality (%) | 330 (34.4) | 670 (31.0) | 0.066 | 215 (32.9) | 187 (28.6) | 0.093 |
| Duration of major intervention uses up to 28 days and length of stay (days) | ||||||
| Duration of mechanical ventilation | 5 (2–12) | 3 (0–9) | <0.001 | 5 (2–12) | 3 (0–9) | <0.001 |
| Duration of vasoactive drugs | 3 (2–7) | 3 (0–5) | <0.001 | 3 (2–6.5) | 3 (1–6) | 0.004 |
| Duration of renal replacement therapy | 1 (0–5) | 0 (0–2) | <0.001 | 0 (0–4) | 0 (0–2) | <0.001 |
| Length of stay in ICU | 8 (4–15) | 6 (3–13) | <0.001 | 8 (4–15) | 7 (4–13) | 0.012 |
| Length of stay from ICU admission to discharge | 28 (14–55) | 27 (13–53) | 0.310 | 28 (14–50) | 27 (13–52.5) | 0.743 |
ICU intensive care unit, IVIgG intravenous immunoglobulin G